Study of brain cooling and clot-busting drug therapy for stroke receives FDA OK to expand
An international multicenter clinical trial on the combination of brain cooling and ?clot-busting? drug therapy after stroke has received Food and Drug Administration approval to expand from 50 patients to 400. This study, which includes the use of intravenous tissue plasminogen activator (IV tPA), the only FDA-approved treatment for acute stroke, is the latest in a series of clinical trials on brain cooling ? controlled hypothermia ? to reduce neurological damage after stroke. View full story